Health Care·Pharmaceuticals·$21.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.27 | N/A | +5.26% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.27 | N/A | +5.26% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management acknowledged the challenges ahead without offering detailed forecasts. They emphasized a focus on maintaining operational stability.
Management did not provide specific guidance for future quarters.
The company reported a slight EPS beat despite the lack of revenue figures.
This earnings report indicates that Royalty Pharma managed to beat EPS expectations, although the lack of revenue data leaves uncertainty. The stock reaction is not available, but the overall sentiment may be cautious due to the absence of guidance. Investors will need to monitor future developments closely.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HUMANA INC
Nov 6, 2015